Skip to content
AnalystLens

Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2024

Filing Date
Filed April 23, 2024
Period End
March 31, 2024
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-Q filed April 23, 2024. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported first-quarter 2024 revenue, net of $511.0 milliona, up from $434.1 million in the first quarter of 2023, with the filing stating the increase was broad based but primarily driven by the Metabolic, Oncology, AVAI and Other therapeutic areas.

Income from operations was $104.1 millionb versus $86.2 million a year earlier, and net income was $102.6 million, compared with $72.9 million. Diluted EPS was $3.20 versus $2.27. The effective tax rate fell to 9.0% from 15.3%, which the company attributed mainly to excess tax benefits from share-based compensation and Foreign Derived Intangible Income benefits.

Backlog rose to $2,907.1 millionc as of March 31, 2024, up $447.0 million, or 18.2%, from $2,460.1 million a year earlier. Net new business awards were $615.6 million for the quarter, compared with $555.8 million in the prior-year quarter. Net cash provided by operating activities was $152.7 million, helped by a $56.8 million increase in advanced billings.

Cash and cash equivalents rose to $407.0 milliond from $245.4 million at December 31, 2023. The company made no share repurchases in the quarter, leaving $308.8 million of authorization under its $500.0 million program. It had no indebtedness at March 31, 2024.

The credit facility was reduced to a $10.0 million revolving line, with $10.0 million available for borrowing. Shareholders' equity increased to $671.5 million from $558.9 million.

Key Highlights

  1. Revenue, net rose 17.7% to $511.0 million from $434.1 million, with growth in the Metabolic, Oncology, AVAI and Other therapeutic areas.
  2. Net income more than doubled? No: net income rose to $102.6 million from $72.9 million, and diluted EPS was $3.20 versus $2.27.
  3. Backlog increased 18.2% to $2,907.1 million at March 31, 2024, with net new business awards of $615.6 million in the quarter versus $555.8 million a year earlier.
  4. The effective tax rate was 9.0%, down from 15.3%, driven mainly by excess share-based compensation tax benefits and FDII benefits.
  5. Cash and cash equivalents increased to $407.0 million from $245.4 million, supported by $152.7 million of operating cash flow.
  6. No share repurchases were executed in Q1 2024, leaving $308.8 million of remaining authorization under the $500.0 million program.
  7. The company had no indebtedness at March 31, 2024, and its credit facility was reduced to a $10.0 million revolving line of credit.

Financial Statements

Q1 FY2024 against Q1 FY2023

Line itemQ1 FY2024Q1 FY2023Change
Revenue$511.04M$434.07M+17.7%
SG&A Expenses$44.08M$38.03M+15.9%
Operating Expenses$406.98M$347.87M+17.0%
Operating Income$104.07M$86.20M+20.7%
Net Income$102.59M$72.89M+40.7%
EPS (Basic)$3.32$2.35+41.3%
EPS (Diluted)$3.20$2.27+41.0%
Shares Outstanding (Basic)30.84M31.01M−0.5%
Shares Outstanding (Diluted)32.00M32.16M−0.5%

Frequently Asked Questions

  1. How did Medpace's revenue and profitability trend in the first quarter of 2024?

    Revenue, net was $511.0 million, up $77.0 million from $434.1 million. Income from operations was $104.1 million versus $86.2 million, and net income was $102.6 million versus $72.9 million. The income tax provision decreased to $10.2 million from $13.1 million.

  2. What does the backlog and new business activity indicate?

    Backlog was $2,907.1 million at March 31, 2024, up $447.0 million, or 18.2%, from $2,460.1 million a year earlier. The company stated that approximately $1,550.0 million to $1,570.0 million of backlog is expected to convert to net revenue over the next twelve months. Net new business awards were $615.6 million, compared with $555.8 million in the prior-year period.

  3. Why did the effective tax rate decline?

    The effective tax rate was 9.0%, compared with 15.3% a year earlier. The company attributed the decrease mainly to an increase in excess tax benefits recognized from share-based compensation and tax benefits related to Foreign Derived Intangible Income (FDII).

  4. How is the company's liquidity and capital position?

    Cash and cash equivalents were $407.0 million at March 31, 2024, up from $245.4 million at December 31, 2023. The company had no indebtedness, and $10.0 million was available under its credit facility. Total shareholders' equity increased to $671.5 million from $558.9 million.

  5. Did Medpace repurchase shares during the quarter?

    No. The company did not execute any share repurchases during the three months ended March 31, 2024. It had $308.8 million of remaining authorization under its stock repurchase program as of March 31, 2024.